Fortekor Plus

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

benazepril hidroklorid, pimobendan

Available from:

Elanco GmbH

ATC code:

QC09BX90

INN (International Name):

benazepril, pimobendan

Therapeutic group:

Psi

Therapeutic area:

Zaviralci ACE, kombinacije

Therapeutic indications:

Za zdravljenje kongestivnega srčnega popuščanja zaradi atrioventrikularne ventilske insuficience ali dilatirane kardiomiopatije pri psih.

Product summary:

Revision: 4

Authorization status:

Pooblaščeni

Authorization date:

2015-09-08

Patient Information leaflet

                                16
B. NAVODILO ZA UPORABO
17
NAVODILO ZA UPORABO
FORTEKOR PLUS 1,25 MG/2,5 MG TABLETE ZA PSE
FORTEKOR PLUS 5 MG/10 MG TABLETE ZA PSE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Elanco GmbH
Heinz-Lohmann-Str. 4
27472 Cuxhaven
Nemčija
Proizvajalec, odgovoren za sproščanje serij:
Elanco France S.A.S.
26 Rue de la Chapelle
F-68330 Huningue
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
FORTEKOR PLUS 1,25 mg/2,5 mg tablete za pse
FORTEKOR PLUS 5 mg/10 mg tablete za pse
pimobendan/benazeprilijev klorid
3.
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN
Vsaka tableta vsebuje:
UČINKOVINI:
pimobendan
benazeprilijev
klorid
FORTEKOR PLUS 1,25 mg/2,5 mg tablete
1,25 mg
2,5 mg
FORTEKOR PLUS 5 mg/10 mg tablete
5 mg
10 mg
POMOŽNA SNOV:
rjavi železov
oksid (E172)
FORTEKOR PLUS 1,25 mg/2,5 mg tablete
0,5 mg
FORTEKOR PLUS 5 mg/10 mg tablete
2 mg
Tablete so dvoplastne, ovalne, bele in svetlo rjave ter se lahko
vzdolž zareze razpolovijo na enaki
polovici.
18
4.
INDIKACIJA(E)
Za zdravljenje kongestivnega srčnega popuščanja zaradi insuficience
atrioventrikularne zaklopke ali
dilatativne kardiomiopatije pri psih. FORTEKOR PLUS je kombinirano
zdravilo in se sme uporabljati
samo pri živalih, pri katerih klinične znake uspešno nadzorujemo s
sočasnim dajanjem enakih
odmerkov posameznih komponent (pimobendana in benazeprilijevega
klorida).
5.
KONTRAINDIKACIJE
Ne uporabite pri nezadostnem minutnem volumnu srca zaradi aortne ali
pljučne stenoze.
Ne uporabite pri hipotenziji (nizkem krvnem tlaku), hipovolemiji
(premajhnem volumnu krvi),
hiponatriemiji (nizki ravni natrija v krvi) ali akutni odpovedi
ledvic.
Ne uporabite pri psicah v obdobju brejosti in laktacije (glejte
poglavje »POSEBNO(A)
OPOZORILO(A)«).
Ne uporabite v primerih preobčutljivosti na pimobendan,
benazeprilijev klorid ali katero koli
pomožno snov v tabletah.
6.
NEŽELENI UČINKI
Pimobendan
Zmeren pozitivni kronotropni uč
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
FORTEKOR PLUS 1,25 mg/2,5 mg tablete za pse
FORTEKOR PLUS 5 mg/10 mg tablete za pse
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsaka tableta vsebuje:
UČINKOVINI:
pimobendan
benazeprilijev
klorid
FORTEKOR PLUS 1,25 mg/2,5 mg tablete
1,25 mg
2,5 mg
FORTEKOR PLUS 5 mg/10 mg tablete
5 mg
10 mg
POMOŽNA SNOV:
rjavi železov
oksid (E172)
FORTEKOR PLUS 1,25 mg/2,5 mg tablete
0,5 mg
FORTEKOR PLUS 5 mg/10 mg tablete
2 mg
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tablete.
Bele in svetlo rjave ovalne dvoplastne tablete z zarezo na obeh
straneh.
Tablete lahko razpolovimo na enaki polovici.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Za zdravljenje kongestivnega srčnega popuščanja zaradi insuficience
atrioventrikularne zaklopke ali
dilatativne kardiomiopatije pri psih. FORTEKOR PLUS je kombinirano
zdravilo in se sme uporabljati
samo pri živalih, pri katerih klinične znake uspešno nadzorujemo s
sočasnim dajanjem enakih
odmerkov posameznih komponent (pimobendana in benazeprilijevega
klorida).
4.3
KONTRAINDIKACIJE
Ne uporabite pri hipertrofični kardiomiopatiji ali kliničnih
stanjih, pri katerih povečanje minutnega
volumna srca ni mogoče zaradi funkcionalnih ali anatomskih razlogov
(npr. aortne ali pljučne
stenoze).
Ne uporabite pri hipotenziji, hipovolemiji, hiponatriemiji ali akutni
odpovedi ledvic.
Ne uporabite v obdobju brejosti in laktacije (glejte poglavje 4.7).
Ne uporabite v primerih preobčutljivosti na učinkovini ali na katero
koli pomožno snov.
3
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Jih ni.
4.5
POSEBNI PREVIDNOSTNI UKREPI
Posebni previdnostni ukrepi za uporabo pri živalih
V primerih kronične bolezni ledvic se priporoča, da pred začetkom
zdravljenja preverite stanje
hidracije psa ter da med zdravljenjem spremljate ravni kreatinina v
plazmi in število eritrocitov v krvi.
Ker se pimobendan 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-03-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-03-2021
Public Assessment Report Public Assessment Report Bulgarian 08-10-2015
Patient Information leaflet Patient Information leaflet Spanish 23-03-2021
Public Assessment Report Public Assessment Report Spanish 08-10-2015
Patient Information leaflet Patient Information leaflet Czech 23-03-2021
Public Assessment Report Public Assessment Report Czech 08-10-2015
Patient Information leaflet Patient Information leaflet Danish 23-03-2021
Public Assessment Report Public Assessment Report Danish 08-10-2015
Patient Information leaflet Patient Information leaflet German 23-03-2021
Public Assessment Report Public Assessment Report German 08-10-2015
Patient Information leaflet Patient Information leaflet Estonian 23-03-2021
Public Assessment Report Public Assessment Report Estonian 08-10-2015
Patient Information leaflet Patient Information leaflet Greek 23-03-2021
Public Assessment Report Public Assessment Report Greek 08-10-2015
Patient Information leaflet Patient Information leaflet English 23-03-2021
Public Assessment Report Public Assessment Report English 08-10-2015
Patient Information leaflet Patient Information leaflet French 23-03-2021
Public Assessment Report Public Assessment Report French 08-10-2015
Patient Information leaflet Patient Information leaflet Italian 23-03-2021
Public Assessment Report Public Assessment Report Italian 08-10-2015
Patient Information leaflet Patient Information leaflet Latvian 23-03-2021
Public Assessment Report Public Assessment Report Latvian 08-10-2015
Patient Information leaflet Patient Information leaflet Lithuanian 23-03-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-03-2021
Public Assessment Report Public Assessment Report Lithuanian 08-10-2015
Patient Information leaflet Patient Information leaflet Hungarian 23-03-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 23-03-2021
Public Assessment Report Public Assessment Report Hungarian 08-10-2015
Patient Information leaflet Patient Information leaflet Maltese 23-03-2021
Public Assessment Report Public Assessment Report Maltese 08-10-2015
Patient Information leaflet Patient Information leaflet Dutch 23-03-2021
Public Assessment Report Public Assessment Report Dutch 08-10-2015
Patient Information leaflet Patient Information leaflet Polish 23-03-2021
Public Assessment Report Public Assessment Report Polish 08-10-2015
Patient Information leaflet Patient Information leaflet Portuguese 23-03-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 23-03-2021
Public Assessment Report Public Assessment Report Portuguese 08-10-2015
Patient Information leaflet Patient Information leaflet Romanian 23-03-2021
Public Assessment Report Public Assessment Report Romanian 08-10-2015
Patient Information leaflet Patient Information leaflet Slovak 23-03-2021
Public Assessment Report Public Assessment Report Slovak 08-10-2015
Patient Information leaflet Patient Information leaflet Finnish 23-03-2021
Public Assessment Report Public Assessment Report Finnish 08-10-2015
Patient Information leaflet Patient Information leaflet Swedish 23-03-2021
Public Assessment Report Public Assessment Report Swedish 08-10-2015
Patient Information leaflet Patient Information leaflet Norwegian 23-03-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 23-03-2021
Patient Information leaflet Patient Information leaflet Icelandic 23-03-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 23-03-2021
Patient Information leaflet Patient Information leaflet Croatian 23-03-2021
Public Assessment Report Public Assessment Report Croatian 08-10-2015

View documents history